Bifogade filer
20240319_Isofol_Solasia intensifies its commitment
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the clinical development program presented by Isofol today.
The information in the press release is intended for investors.
In 2020, Solasia acquired the exclusive rights for arfolitixorin (SP-05) in Japan and participated in the phase III clinical trial AGENT that was concluded in 2022. After exchanging information with Isofol about its forward strategy and updated clinical development plan for arfolitixorin, Solasia resolved to participate in the continued development of the project.
Solasia will participate in the ongoing process to define the details of the development program led by Isofol and discuss development schedules, clinical trial designs and related matters.
”We have solid confidence in our development project and are convinced that it is the right decision to give arfolitixorin another chance to prove itself in clinical trials. Getting this strong message from our collaboration partner is gratifying and confirms that key stakeholders in the field see the potential in arfolitixorin to improve the prognosis for a group of patients with a high medical need. Japan is the second biggest addressable market for arfolitixorin after the U.S., which makes Solasia’s decision even more important from a commercial perspective,” says Petter Segelman Lindqvist, CEO of Isofol.
Yoshihiro Arai, President & CEO of Solasia Pharma K.K. comments: ”We have been working closely with Isofol on the clinical trial (AGENT study) of arfolitixorin (SP-05) since licensing the Japanese rights of arfolitixorin in 2020. We are very pleased to once again have the opportunity to collaborate with Isofol on a more robust clinical development program of arfolitixorin.”
Investor meeting March 19
Today, March 19, Isofol is presenting its strategy and a clinical development plan for the continued development of its drug candidate arfolitixorin. The aim is to initiate a phase I/II clinical trial before the end of 2024 in order to document the efficacy and safety of a new dosing regimen.
The presentation will be available on Isofol's website afterwards.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, CEO
E-mail: petter.s.lindqvist@isofolmedical.com
Telephone: +46 (0)739 60 12 56
This is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:37 CET, on March 19, 2024.
About Solasia Pharma K.K.
Solasia is a specialty pharmaceutical company based in Asia, with a mission of “Better Medicine for a Brighter Tomorrow”. In order to address the unmet medical needs within the oncology area, the company develop innovative medicines to contribute to the patient’s healthy living and to provide treatment options for the healthcare providers.
www.solasia.co.jp/en/
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com